Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I could buy controlling interest in this company for $2.4m. Fire the CEO. Phase II is years away from a successful P-3 double blind. Of which would cost $200m. What could happen here is a consortium could come in and buy up 50% of the shares then juice the pump and sell them at $3.00 a share. But yes. Looks absolutely terrible here.
Don’t get shook here this thang will have it’s day soon atlesst 50% bag
$BPTH - 👆Up 20% Pre-Market/ Current Price $1.29
👉Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
Anyway, pps has been climbing slowly & steadily the last month.
kool i hope this start running fda clear
AH will be interesting not selling $$$$$
kool got filled 6.32 ??
Hasn’t been blood all day nothing but green $$$$$$
Profitability
Profit Margin 0.00%
Operating Margin 0.00%
Management Effectiveness
Return on Assets -25.12%
Return on Equity -42.71%
Cash Flow Statement
Operating Cash Flow -9.17M
Levered Free Cash Flow -5.47M
Only phase 1. With 6 patients... Every old pop, drops for days.
* * $BPTH Video Chart 04-05-2021 * *
Link to Video - click here to watch the technical chart video
Analyst Actions: Roth Capital Starts Bio-Path Holdings at Buy With $13 Price Target
Nice call, thanks!
BTW: Gave you membermark #268
Regards Ih
As I said on the 10th when it was $12+...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161702058
Turn out to be a pos pump and dump imo
round trip is about complete
* * $BPTH Video Chart 02-10-2021 * *
Link to Video - click here to watch the technical chart video
Anyone know a broker that will let you short this?
I virtually never short stocks, but this is a no-brainer!
$BPTH:
it can hit $30 after hours today.
there are damn no shares left to be had.
shorts are going to get destroyed.
Well, it's 3 of them..... took in some profits at $22 to $23 per share this morning. Glad I did, now it's in the $16 range. With that said, this reminds me of what happened 2 years ago in March when over a 3 day trading period, the stock shot up and down and was a perfect day trading stock for a time! It hit a high of nearly $80.00 and would have some $20 to $30 swings in a single day..... made some very GOOD money that 3 days. I'd love to see it hit those highs again. I have my remaining shares set for a $50.00 sell (for the day). Don't know if it's gonna hit that today. Keep an eye on it.
Thanks. Must be the best patent they have ever had
BPTH receives 3rd patent!
Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology
Wow! Up over $10 with 23 mil vol. What's happening here?
Looking for that power bounce today on BPTH
Micro-Float...Bought some today 3.83...Glta
Tomorrow will be INSANE
Great, they have started Phase 1 of BP 2001. The web site says:
BP1002 (Liposomal Bcl2 Antisense)
Bio-Path is planning to initiate a Phase 1 clinical trial of BP1002 in patients with follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL) in 2017.
so they are only 3 3/4 years behind schedule. Meanwhile PN is taking a huge salary drawing down the limited funds.
The proxy is out and includes a shareholder resolution relating to the CEO
Followers
|
100
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6351
|
Created
|
03/26/13
|
Type
|
Free
|
Moderators |
The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.
Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive.
A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson.
Patent protection for manufacturing their neutral lipid delivery system has been granted.
http://www.biopathholdings.com
This link to the company website describes their delivery technology:
http://biopathholdings.com/technology/
The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 2+ million in cash. BIO-PATH'S viability is in question due to a lack of funds.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |